ArticleACS omega2026
Albumin Precoating of Nanoparticles: A Reliable Stealth Strategy?
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Albumin precoating has emerged as a strategy to impart nanoparticles (NPs) with stealth-like properties and as an alternative to NP surface PEGylation. Yet how such coatings influence protein corona formation and hemocompatibility in human blood remains poorly understood. To address this, we precoated model hydrophilic and hydrophobic polystyrene NPs with either fatted or defatted human serum albumin (HSA) and exposed them to human plasma and blood-based models. Proteomic analysis of the adsorbed protein corona revealed formulation-dependent differences in composition, but an overall favorable profile characterized by enrichment of dysopsonins (HSA and apolipoproteins) and depletion of major opsonins (complement proteins and immunoglobulins). Consistent with these findings, NP uptake by phagocytic blood cells was low across all formulations. However, evaluation in physiologically relevant human-derived models uncovered formulation-dependent biological responses. Specifically, three of the four HSA-precoated NPs exhibited complement activation or prothrombotic tendencies, whereas fatted HSA on hydrophobic NPs showed consistent blood compatibility across multiple assays. Taken together, these findings demonstrate that the hemocompatibility of albumin-coated NPs is determined by the interplay between NP core surface chemistry and albumin formulation, rather than by albumin precoating alone, providing important design criteria for albumin-based NP coatings.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.